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Abstract
Aims/Hypothesis: There is controversy with respect to molecular characteristics of insulin analogues. We report a series of
experiments forming a comprehensive characterisation of the long acting insulin analogues, glargine and detemir, in
comparison with human insulin, IGF-1, and the super-mitogenic insulin, X10.
Methods: We measured binding of ligands to membrane-bound and solubilised receptors, receptor activation and
mitogenicity in a number of cell types.
Results: Detemir and glargine each displayed a balanced affinity for insulin receptor (IR) isoforms A and B. This was also true
for X10, whereas IGF-1 had a higher affinity for IR-A than IR-B. X10 and glargine both exhibited a higher relative IGF-1R than
IR binding affinity, whereas detemir displayed an IGF-1R:IR binding ratio of #1. Ligands with high relative IGF-1R affinity also
had high affinity for IR/IGF-1R hybrid receptors. In general, the relative binding affinities of the analogues were reflected in
their ability to phosphorylate the IR and IGF-1R. Detailed analysis revealed that X10, in contrast to the other ligands, seemed
to evoke a preferential phosphorylation of juxtamembrane and kinase domain phosphorylation sites of the IR. Sustained
phosphorylation was only observed from the IR after stimulation with X10, and after stimulation with IGF-1 from the IGF-1R.
Both X10 and glargine showed an increased mitogenic potency compared to human insulin in cells expressing many IGF-
1Rs, whereas only X10 showed increased mitogenicity in cells expressing many IRs.
Conclusions: Detailed analysis of receptor binding, activation and in vitro mitogenicity indicated no molecular safety
concern with detemir.
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Introduction
Increased interest in molecular safety of insulin analogues was
stimulated by four epidemiological studies in this Journal in June
2009 [1–4], three of which suggested an association between the
use of insulin glargine (glargine) and cancer [1–3]. A subsequent
case-control study also suggested an association between glargine
and an increased cancer risk, although this finding was restricted
to high doses of glargine ($3IU/kg/day) [5]. These studies have
not been without criticism [6] and, unfortunately, at present the
available randomised controlled trials (RCTs) are of quite limited
size [7]. In addition, traditional animal toxicological studies with
long-acting insulin analogues have been restricted to limited dose
ranges due to death from hypoglycemia at escalated doses.
Therefore, emphasis has now been put on the molecular
characteristics of insulin analogues during safety evaluation.
The potential for modified insulin molecules to possess in-
creased mitogenic potencies relative to human insulin has been
recognised ever since a prototype rapid-acting analogue, insulin
X10 (B10Asp), was found to dose-dependently increase the
incidence of mammary tumours in female Sprague-Dawley rats
[8,9]. Subsequent investigations showed this analogue to have
increased affinity for the IGF-1 receptor (insulin-like growth factor
1) (IGF-1R) relative to the insulin receptor (IR), in contrast to
human insulin and other analogues not showing increased
mitogenicity [10–13]. In addition, insulin X10 (X10) had in-
creased residence time at the IR, eliciting prolonged IR activation
[10,14]. Each of these properties represents a feasible mechanism
by which X10 could evoke an increased mitogenic response
compared to human insulin (Fig. 1) [7,9].
Despite renewed investigations into the molecular safety
characteristics of insulin analogues, studies have produced
conflicting results [15]. In order to clarify some of the remaining
uncertainties and resolve some of the inconsistencies from earlier
research, we have undertaken a comprehensive series of experi-
ments employing robust laboratory methodologies. In this study,
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insulin analogues with regard to receptor binding, receptor
activation, duration of receptor activation in cells expressing IR-
A, IR-B or IGF-1R, and mitogenic potency in two different cell
types. Human insulin was included as the reference control, and
the known mitogens IGF-1 and X10 as positive controls. In order
to perform these experiments in a meaningful way allowing
comparison among different ligands it is critical to perform full-
dose response curves [7]. It is equally critical to use cells of
identical age/life-cycle to obtain an adequate mitogenic response
[16].
Methods
Materials
Human insulin, insulin detemir (detemir), glargine, X10 and
IGF-1 were produced by recombinant DNA techniques and
purified at Novo Nordisk A/S (Diabetes Research Unit, Ma ˚løv,
Denmark). Long R3 IGF-1 (LR3-IGF-1, Sigma-Aldrich, Stein-
heim, Germany) was employed instead of IGF-1 for stimulation of
IGF-1 receptor activity in order to avoid confounding effects from
IGF binding proteins.
125I-labelled human insulin and
125I-
labelled human IGF-1 were prepared at Novo Nordisk A/S
(CMC Supply, Ma ˚løv, Denmark). For binding assays, human IR
and human IGF-1R were semipurified either by homogenisation
and centrifugation (membrane-associated receptors) or by wheat
germ agglutinin (solubilised receptors) from baby hamster kidney
(BHK) cells stably transfected with the pZem219B vector contain-
ing the human IR-A, IR-B or IGF-1R cDNAs alone or in
combination [17]. Other chemicals were of reagent grade. The
IR-specific antibody 83–7 and the IGF-1R-specific antibody 24–
31 were licensed from Professor K. Siddle, University of Cam-
bridge, UK [18,19].
Receptor Number
Receptors were quantified using QIFIKIT (Dako, Denmark)
according to manufacturer’s protocols using either the murine
monoclonal antibody 83–7 against the human IR, 24–31 against
the human IGF-1R, or an isotype control antibody. Cells were
analysed using an LSRFortessa (BD Biosciences, Franklin Lakes,
NJ, USA).
Receptor Binding
The relative binding affinities of the study ligands for the two IR
isoforms and for the IGF-1R were measured using both solubilised
and membrane-associated receptor systems.
Receptor binding assays (solubilised receptors). The
relative binding affinities of the study ligands for either solubilised
human IR-A or IR-B were determined by competition binding in
a scintillation proximity assay (SPA) setup as previously published
[20]. In brief, dilution series in quadruplicate of human insulin and
insulin analogues were performed in 96-well Optiplates (Perkin-
Elmer Life Sciences, Boston, MA, USA) followed by the addition
of SPA beads (Anti-Mouse polyvinyltoluene [PVT] SPA Beads,
GE Healthcare, Waukesha, WI, USA), anti-IR mouse antibody
83–7, solubilised IR-A or IR-B, and [
125I-TyrA14]-human insulin
in a binding buffer consisting of 100 mM HEPES (pH 7.8),
100 mM NaCl, 10 mM MgSO4, and 0.025% (v/v) Tween 20
(Tween 20 was added to avoid adhesion of insulin to the assay
plate). Increasing concentrations of human insulin or insulin
analogue was used, typically between 0.001 and 30 nM. Plates
were incubated with gentle shaking for 24 h at 22uC, centrifuged
at 2000 rpm for 2 minutes and counted on a TopCount NXT
(Perkin-Elmer Life Sciences). IGF-1R assays were conducted
essentially as for the IR binding assays except that solubilised IGF-
1 receptors and [
125I-Tyr31]-human IGF-1 were employed.
Receptor binding assays (membrane-associated
receptors). The relative binding affinities of the different
ligands for either the membrane-associated human IR-A or IR-
B were determined by competition binding in a SPA setup. Assays
were performed in duplicate in 96-well OptiPlates (Perkin-Elmer
Life Sciences). Membrane protein was incubated with gentle
agitation for 150 minutes at 25uC with 50 pM [
125I-TyrA14]-
human insulin in a total volume of 200 ml assay buffer (50 mM
HEPES, 150 mM NaCl, 5 mM MgSO4, 0.01% Triton X2100,
0.1% ovalbumin, Complete EDTA-free protease inhibitors), 50 mg
of wheat germ agglutinate (WGA)-coated PVT microspheres (GE
Healthcare) and increasing concentrations of ligand (typically
between 0.01 and 1,000 nM). The assays were terminated by
centrifugation of the plate at 2000 rpm for 2 minutes and bound
radioactivity quantified by counting in a TopCount NXT (Perkin-
Elmer Life Sciences). IGF-1R assays were conducted essentially as
for the IR binding assays except that membrane-associated IGF-1
receptors and 50 pM [
125I-Tyr31]-human IGF-1 were employed.
Hybrid Receptor Binding
WGA purification of solubilised receptors: cells were lysed in
50 mM HEPES pH 8.0, 150 mM NaCl, 1% Triton X2100,
2 mM EDTA, 10% glycerol. The cleared cell lysate was batch
absorbed with WGA-agarose (Lectin from Triticum vulgaris-
Agarose, L1394, Sigma-Aldrich) for 90 minutes. After 20 volumes
of washes with 50 mM HEPES pH 8.0, 150 mM NaCl, 0.1%
Triton X2100, the receptors were eluted with 50 mM HEPES,
pH 8.0, 150 mM NaCl, 0.1% Triton X2100, 0.5 M N-acetyl
glucosamine, 10% glycerol. All buffers contained Complete
(Roche Diagnostic GmbH, Mannheim, Germany).
SPA for hybrid receptors: WGA- purified hybrid receptors of
both isoforms of IR were used. SPA PVT anti-mouse beads
(Perkin-Elmer Life Sciences) were incubated with IR antibody 83–
7 and hybrid receptors for five hours at room temperature. The
SPA beads were washed twice with buffer to remove homodimer
IGF-1R and any other receptors not bound to the SPA beads, and
125I-IGF-1 was added. Dilution series of ligands were prepared in
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Figure 1. Potential mechanisms influencing the balance of
metabolic and mitogenic actions of insulin-like molecules.
Reprinted with kind permission from Springer Science & Business
Media: Hansen et al. [9], Fig. 2. IGF-1, insulin-like growth factor 1.
doi:10.1371/journal.pone.0034274.g001
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concentration of
125I-IGF-1 was 5000 cpm/200 ml and the buffer
composition was 100 mM HEPES, pH 7.8, 100 mM NaCl,
10 mM MgSO4, 0.025% Tween-20. The plate was rocked gently
for 18 hours at room temperature, centrifuged and counted in
a TopCounter. IC50 values were determined using non-linear
regression algorithm in GraphPad Prism 5.0 (GraphPad Software
Inc., San Diego, CA, USA).
Receptor Activation/deactivation
IR activation. Activation of the two IR isoforms was assessed
by the ability of the study ligands to phosphorylate three sites
chosen from the three main regions of the IR beta unit, namely J
(Juxtamembrane), K (Kinase) and C (C-peptide). The respective
phosphorylation sites were (using IR-B terminology) 972 (=960
for IR-A), 1158 (=1146 for IR-A) and 1334 (=1322 for IR-A).
BHK cells overexpressing either IR-A, IR-B or IGF-1R were
seeded in 12-well plates and grown until 90–100% confluence in
DMEM (GibcoH, Invitrogen, Carlsbad, CA, USA) containing
10% FBS, 100 mg/ml penicillin and 100 U/ml streptomycin.
Cells were stimulated with increasing concentrations of ligands (0–
1000 nM) for 30 min in DMEM (GibcoH) medium containing
0.1% human serum albumin (HSA). Subsequently, cells were
washed three times in ice-cold phosphate buffered saline (PBS) and
snap-frozen by pouring liquid N2 into the wells. Cells were lysed in
100 mL lysis buffer (cell extraction buffer from BioSource,
Invitrogen, Carlsbad, CA, USA; 1 mM AEBSF, and protease
inhibitor cocktail from Sigma-Aldrich). Protein concentrations
were measured with Pierce BCA Protein Assay Kit and equal
amounts of protein loaded into Phospho-IR-ELISA wells
(IR(pY972), IR(pY1158) and IR(pY1334) (Invitrogen). Phosphor-
ylation of the three representative sites was measured according to
the manufacturer’s protocol (Invitrogen).
IGF-1R Activation. Cells were grown as stated above and
stimulated with ligands and lysates prepared as for IR activation.
Lysates were analysed for IGF-1R activation by Western blotting
using an anti-phospho-IGF-1R antibody (Ab5681 Abcam, Cam-
bridge, UK) diluted 1:1000 in Starting Block T20 Tris buffered
saline (TBS) Blocking buffer (Thermo # 37543) and incubated
overnight at 4uC with slight agitation. Subsequently, blots were
incubated with secondary antibody (goat anti-rabbit IgG HRP
170–6515, Bio-Rad, California, USA) diluted 1:3000 in Starting
Block T20 (TBS) Blocking buffer (Thermo # 37543) and
incubated for 1 hr at RT. Phosphorylated IGF-1R was visualised
using SuperSignal West Pico Chemoluminescent Substrate
(Thermo Scientific, Waltham, MA, USA) and band intensities
quantified using a Fuji Imager LAS3000.
Duration of Activation. To evaluate the duration of signal
after stimulation with ligands, cells were incubated for 30 min
(10 and 30 nM [X10], 100 and 300 nM [human insulin and
glargine], 1000 and 10,000 nM [detemir and IGF-1R]) in
DMEM (GibcoH) medium containing 0.1% HSA, 100 mg/ml
penicillin, 100 U/ml streptomycin and washed thoroughly three
times in pre-warmed medium containing 0.1% HSA. Sub-
sequently, cells were incubated for 0–5–10–20–30–45–60 min at
37uC whereupon phosphorylations of IR or IGF-1R were
measured as described above. Phosphorylation at t=0 was
defined as 100%. Results were calculated as the average of the
two applied concentrations for each ligand.
Cell Mitogenicity
Mitogenicity of the study ligands was measured in two cell types:
human mammary epithelial cells (HMEC) (obtained from Lonza,
Basel, Switzerland, as cryopreserved cells at passage number 7),
which express predominantly IGF-1R (,21 times more IGF-1R
than IR), and L6-myoblasts. The L6 muscle cells were obtained
from ATCC and stably transfected with human insulin receptors
to over-express human IR-A [16]. Thus, the L6-hIR cells express
,200 times more IR compared to HMEC.
The HMECs were cultured in mammary epithelial growth
medium (MEGMH) containing bovine insulin (5 mg/ml), bovine
pituitary extract (50 mg/ml), hydrocortisone (0.5 mg/ml), epider-
mal growth factor (10 ng/ml) and gentamicin/amphotericin-B.
Cells were passaged, at most, eight times covering approximately 5
weeks.
For mitogenicity experiments, cells were seeded at a density of
4610
3 cells/well in 96-well plates and incubated for 24 h in assay
medium (mammary epithelial basal medium [MEBMH] contain-
ing bovine pituitary extract [50 mg/ml], hydrocortisone [0.5 mg/
ml], epidermal growth factor [10 ng/ml] and gentamicin/
amphotericin-B) after which dilution series of ligands were added.
Plates were incubated for 72 h at which 0.125 mCi/well [3H]-
thymidine was added at t =70 h. Cells were harvested using a cell
harvester and scintillation liquid added to the dried filter plates
after which radioactivity was counted in a TopCount NXT (all
from Perkin-Elmer Life Sciences). L6-hIR cells were cultured in
growth medium consisting of DMEM, 10% bovine serum, 100 U/
ml penicillin, 100 mg/ml streptomycin, 2 mM glutamine, 1 mg/
ml Geneticin (all from Gibco, Invitrogen), and 1 mM human
insulin (ActrapidH, Novo Nordisk). Cells were passaged at most 30
times and subcultured every 2–3 days.
For mitogenicity experiments, L6-hIR cells were synchronised
by topoinhibition (48 hrs) and serum starvation (24 hrs) prior to
stimulation with test compounds [16].
Synchronised and starved L6-hIR cells were harvested and
seeded at a density of 4610
4 cells/well in 96-well plates and
incubated for 1 h in assay medium (DMEM, 0.1% FCS (foetal calf
serum), 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM
glutamine, 1 mg/ml Geneticin (all from Gibco, Invitrogen), after
which dilution series of ligands were added. Plates were incubated
for approximately 18 hrs at which 0.125 mCi/well [3H]-thymi-
dine was added. After 2 hrs of incubation, cells were harvested
using a cell harvester and scintillation liquid added to the dried
filter plates after which radioactivity was counted in a TopCount
NXT (all from Perkin-Elmer Life Sciences).
Data Analysis. In accordance with the European Pharma-
copoeia [21], IR and IGF-1R receptor binding data were fitted
using a four parameter sigmoidal algorithm developed for
bioassays [22]. The binding affinities of the analogues were
calculated relative to that of the human insulin standard
[IC50(insulin)/IC50(analogue) 6 100%] measured within the
same plate. For stimulatory responses, the dose-response curves
were fitted by non-linear regression using GraphPad Prism 5
(GraphPad Software Inc.) and potencies were calculated (if
appropriate) relative to that of the human insulin standard
[EC50 (insulin)/EC50 (analogue) 6100%].
Results
IR and IGF-1R Binding
The relative binding affinities for the long-acting insulin
analogues, X10 and IGF-1 are summarised in Table 1 and
examples of full dose-response curves from competition binding
experiments are presented in Fig. 2. The binding affinities of the
insulin analogues for both the A and B isoform of the IR as well as
the IGF-1R were determined using both solubilised and mem-
brane-bound receptor systems. All the insulin analogues tested
displayed a balanced IR-A to IR-B binding affinity ratio, whereas
Receptor Binding & Mitogenicity: Insulin Analogues
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lower receptor binding affinities in the membrane-bound receptor
systems compared to the solubilised receptor assay, reflecting the
fact that ovalbumin is present in the binding assay with the
membrane-bound, but not the solubilised receptors. Detemir
exhibited both a decreased IR and IGF-1R affinity compared to
human insulin and displayed a IGF-1R:IR affinity ratio of #1
relative to human insulin. Glargine bound to the IR with an
affinity closer to that of human insulin, but showed a 7- to 10-fold
increase in binding affinity for the IGF-1R relative to human
insulin. X10 displayed a 2- to 3-fold increase for the IR, while the
binding affinity for the IGF-1R was increased 4- to 5-fold. As
expected, the IR binding affinity of IGF-1 was low compared to
human insulin, whereas a large increase in IGF-1R affinity was
observed.
IR/IGF-1R Hybrid Receptor Binding
Binding of human insulin, IGF-1, X10, glargine and detemir to
hybrid receptors formed between IGF-1R and IR were studied
(Table 2); both splice variants of the hybrid receptors were
examined (Fig. 3). X10 and glargine bound with three-fold higher
affinity than human insulin to hybrid receptors, whereas detemir-
bound with a four-fold decreased affinity to hybrid receptors
compared to human insulin. We did not observe any significant
difference between the hybrid receptor splice variants for any of
the analogues (Table 2).
Receptor Activation
Data for phosphorylation of the three representative regions of
the IR isoforms are shown in Fig. 4 and the calculated relative
potencies given in Table 3. Detemir and glargine showed
a balanced degree of phosphorylation across the three sites, with
relative potencies corresponding to the IR binding affinities. This
was also the case for IGF-1, whereas X10 seemed to induce
proportionately more phosphorylation of the J and K regions
relative to the C region. In agreement with the IR binding data,
glargine and detemir each showed balanced activation potency at
the two isoforms of the IR. Dose-response curves for activation of
IGF-1R by the study ligands relative to human insulin are shown
in Fig. 5. Compared to human insulin, the dose-response curve for
IGF-1R activation was (as expected) greatly left-shifted for IGF-1
(potency ,4000%). The curves were also slightly left-shifted for
glargine and X10 resulting in relative potencies of ,480% and
,250%, respectively. For detemir, the curve was right-shifted,
evidence of a lower potency than human insulin (8%) with respect
to IGF-1R activation.
Duration of Receptor Activation
Data showing the rate of decline of activation (phosphorylation)
by ligand for each of the three studied regions of IR-A, IR-B and
IGF-1R are presented in Fig. 6 and Fig. 7. The rate of decline of
IR phosphorylation was similar for human insulin, detemir and
glargine, suggesting that these ligands evoke very similar signalling
kinetics at both IR isoforms irrespective of the phosphorylation
sites. In contrast, X10 exhibited a slower rate of decline than
human insulin for IR phosphorylation on both IR isoforms and at
all the studied phosphorylation sites. At the IGF-1R, all the insulin
analogues showed a more rapid decline in phosphorylation than
IGF-1 itself. At 60 minutes after stimulation with IGF-1, more
than 60% of the initial phosphorylation was still present, similar to
the observation with X10 at the IR.
Cell Mitogenicity
Relative proportions of human IR and IGF-1R in each cell line
or type are shown in Table 4. Mitogenicity of the studied ligands
was assessed by full dose-response curves for
3H-thymidine
incorporation into DNA as shown in Fig. 8. In L6-hIR cells,
which predominantly express insulin receptors (IR-A), X10
showed a leftward shift in the dose-response curve compared to
human insulin resulting in a relative potency of 619661%, while
glargine and detemir exhibited rightward shifts leading to relative
potencies of 4969% and 962%, respectively (Table 5). The
mitogenic potencies measured in the L6-hIR cells therefore reflect
the relative IR binding affinities for glargine and detemir, but not
for X10, which displays a mitogenic potency in excess of its
binding affinity. In the HMEC cell type, which predominantly
Table 1. Relative binding affinities for insulin receptor isoform A and isoform B and IGF-1 receptors.
Solubilised receptors (Affinity as % of human insulin) Ratio relative to that of human insulin
IR-A IR-B IGF-1R IR-A/IR-B IGF-1R/IR
Human insulin 100 100 100 1 1
Insulin detemir 23622 6 621 0 60.3 1 0.4
Insulin glargine 81688 4 68 727 674 1 8.8
Insulin X10 268627 299641 480631 1 1.7
IGF-1 1.360.1 0.160.01 1717362270 11 13,000–170,000
Membrane-bound
receptors
(Affinity as % of human insulin) Ratio relative to that of human insulin
IR-A IR-B IGF-1R IR-A/IR-B IGF-1R/IR
Human insulin 100 100 100 1 1
Insulin detemir 6615 614 61 1 0.8
Insulin glargine 70612 63613 10446161 1 15.6
Insulin X10 265647 213626 428637 1 1.8
Affinities were determined by insulin competition binding in a scintillation proximity assay; data are means (6 SD) of quadruplicates (solubilised receptors) or duplicates
(membrane-bound receptors).
doi:10.1371/journal.pone.0034274.t001
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stantial leftward shift in their dose-response curves relative to
human insulin, which resulted in increased mitogenic potencies of
10986235% and 6506136%, respectively, whereas detemir again
showed a rightward shift in the dose-response curve and therefore
a decreased mitogenic potency of 1763% relative to human
insulin (Table 5).
Discussion
In the present study we have confirmed earlier results [13]
showing thatdetemirhasanIGF-1R:IRbindingaffinity ratioof#1
relative to human insulin and that detemir displays a dissociation
pattern from the IR, which is similar to that of human insulin.
Consequently,therelativemitogenicpotencyofdetemirincelltypes
predominantlyexpressingeithertheIGF-1R(HMEC)ortheIR(L6-
hIR) is low and corresponds to its IGF-1R and IR affinities. In
contrast, X10 and glargine, relative to human insulin, displayed
higher IGF-1R affinities resulting in relative IGF-1R:IR binding
ratios .1 (versus human insulin), a finding which is in agreement
with previous results [13,23]. In addition, increased phosphoryla-
tion of the IGF-1R after stimulation with glargine has been shown
[24,25]. The increased IGF-1R:IR binding affinity ratio translates
into an increased mitogenic potency for X10 and glargine in cells
which express many IGF-1 receptors. Even though controversies
regarding the mitogenic potency of glargine can be found in
literature(reviewedinHansen[15]),fromthedatapresentedhereas
well as recent data from other groups [23–26] it now seems safe to
conclude that glargine as well as other insulin analogues with
increased relative IGF-1R:IR binding ratios will exhibit an in-
creased mitogenic potency relative to human insulin in cells
expressing many IGF-1 receptors. The relative IGF-1R:IR binding
ratio for IGF-1 itself is much higher than for X10 or glargine, and it
could be argued that compared to IGF-1, insulin analogues would
only have a negligible effect on the IGF-1R. However, it has to be
taken into account that IGF-1 is bound to IGF-1 binding proteins,
andthereforethefreefractionofIGF-1isonlyasmallfractionofthe
totalconcentration.BothSommerfeldetal.[23]andVarewijcketal.
[25] found only a 30-fold difference in EC50 for the activation of
IGF-1R after stimulation with IGF-1R and glargine. Thus the
difference between IGF-1 and glargine in EC50 for activation of
IGF-1R might not be very large, which is also supported by the
present study.
Equilibrium binding studies have revealed that insulin detemir
can displace
125I-insulin from the receptors in a identical manner
to human insulin albeit with a lower potency. However, because of
the albumin binding properties of insulin detemir, the EC50
estimate will depend on the prevailing concentration of albumin
[27]. As human insulin and other insulin analogues with no lipid
side chains attached bind negligibly to albumin, the EC50
estimates do not depend on the albumin concentration in a given
assay. Thus, the degree of right-shift for insulin detemir’s
concentration–response curve increases with increasing albumin
concentrations.
The amount of albumin used in the different assays is
determined partly by historical reasons and partly by the
requirement of assays [13]. Several of the assays used in this
paper can be performed at conditions where no albumin or serum
is added and as such the potencies measured in these assays can be
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Table 2. Relative binding affinities for Hybrid-A (IR-A/IGF-1R) and Hybrid-B (IR-B/IGF-1R).
Ligand binding relative to human insulin (%)
Receptor Human insulin IGF-1 Insulin X10 Insulin detemir Insulin glargine
Hybrid-A 100 60596701 342613 1766 321661
Hybrid-B 100 824362125 4546204 1863 3276101
IC50 values were determined in scintillation proximity assays for displacement of
125I-IGF-1 from receptors with human insulin, IGF-1, insulin X10, insulin detemir or
insulin glargine. Relative binding compared to human insulin binding is given in percent. Data represent mean (6SD) from three independent experiments.
IGF-1, insulin-like growth factor 1.
doi:10.1371/journal.pone.0034274.t002
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In the absence of albumin, the relative potencies of insulin detemir
were estimated to be 17–26%, whereas values in the presence of
albumin were in the range 3–6%. This decrease in relative potency
with increase in the albumin concentration is in accordance with
previous observations [27].
With respect to mitogenic potencies in L6-hIR and HME cells,
the potencies were estimated to be 9% and 17% relative to human
insulin, respectively. With HMEC, it was possible to perform the
assay in total absence of albumin, whereas 0.1% serum was
needed in the case of L6-hIR. The albumin content in serum is
low, but resulted in a slight decrease in potency in L6-hIR cells
compared to HMEC, nevertheless.
Recent studies have suggested that detemir displays an in-
creased IGF-1 like activity and mitogenic potency compared with
human insulin: Weinstein et al. [28] examined a number of cancer
cells and concluded that detemir along with several other insulin
analogues exhibited in vitro proliferative and anti-apoptotic
activities compared to human insulin. However, the responses
obtained in that study were very modest and in dose-response
experiments the authors failed to show any significant effects of
insulin and IGF-1, making conclusions somewhat dubious. In
addition, this study has been criticised for inconsistency in the
experimental methodology applied for the different ligands [29].
Sciacca et al. [30] also reported a mitogenic potency of detemir on
par with that of glargine. However, the authors did not perform
dose-response experiments for the measurement of mitogenic
potencies and the observed responses were very modest. This was
reflected by the lack of effect of the positive control X10 in cells
expressing insulin receptors. When comparing insulin analogues in
cellular systems it is necessary to perform full dose-response curves
and to optimise the assay system to give a proper response (at least
a two-fold difference in maximal response) in order to obtain
meaningful comparison between analogues [7].
In addition, Sciacca et al. [30] also reported an increased IGF-
1R binding affinity for detemir compared with human insulin. In
fact, they reported a higher IGF-1R affinity for detemir than for
X10. This is in sharp contrast to our present findings as well as
previous studies [13,25], which reported significantly reduced
relative IGF-1R binding and activation for detemir when
performing full dose-response curves. The explanation for this
discrepancy must relate to methodological differences. It is possible
that the use of Scatchard plots for analysis of binding affinities as
applied by Sciacca et al. [30] could be an explanation, since this
linear regression method distorts the experimental error. Scatch-
ard transformation also violates the assumptions of linear re-
gression and is therefore only useful for displaying binding data,
which should always be analysed by non-linear regression.
Nevertheless, on the basis of the present and earlier studies
[13,25] it seems safe to conclude that the relative IGF-1R binding
affinity, IGF-1R activation and mitogenic potency of detemir is
significantly lower than that of human insulin and in the same
range as the relative binding affinity for the IR.
No major differences between the three IR phosphorylation
sites examined were seen for detemir or glargine. Thus, the
relative potencies were comparable across the three phosphory-
lation sites, which was also the case for IGF-1. In contrast, there
seems to be a preferential phosphorylation of the Juxtamembrane
site and, to a lesser degree, the kinase domain phosphorylation
sites after stimulation with X10. Potentially, this could be a unique
and interesting feature with super-mitogenic insulin analogues
mediating an increased mitogenic potency via the IR. However,
more experiments are needed to further elaborate on these
findings, for example, using a panel of different insulin analogues
with variable mitogenic potencies. Furthermore, various periods of
stimulation are also required in order to fully explore this
possibility, since it is well-known that insulin analogues with high
receptor affinities often show altered receptor-binding kinetics.
It has been speculated that an increase in the mitogenic
properties of an insulin analogue could alternatively (or addition-
ally) reflect a binding preference for the shorter IR-A isoform of
the IR relative to the longer IR-B isoform [30,31]. This hypothesis
derives from the observation that IR-A has high affinity for
binding insulin-like growth factor 2 (IGF-2) and is extensively
expressed in foetal tissue, where it mediates growth responses. IR-
A expression is also associated with undifferentiated cells, and
over-expression occurs in some cancer cells. This raises the
possibility that this IR isoform may be relevant for the mitogenesis
of cancer cells [31]. In their recent work, Sciacca et al. [30]
reported that detemir displayed a 13-fold difference in the affinity
between IR-B and IR-A in favour of IR-A. This was in sharp
contrast to the present study, where we find a balanced IR isoform
binding, as well as IR isoform activation for detemir, glargine and
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Figure 3. Competition curves for displacement of 125I-IGF-1
from Hybrid-A and Hybrid-B with human insulin IGF-1, insulin
detemir, insulin glargine, insulin X10 or IGF-1 in SPA binding
assay. The graphs are representatives of three experiments. Each point
in the graphs is the mean (6SE) of three measurements. IGF-1, insulin-
like growth factor 1; SPA, scintillation proximity assay.
doi:10.1371/journal.pone.0034274.g003
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e34274X10. We have studied several hundred insulin analogues including
the commercially available insulin analogues and X10 using both
isoforms of the IR [20,32] and have never identified an insulin
analogue with as much as a 13-fold difference in IR isoform
affinity. The discrepancy between our finding and the observation
in IR isoform affinity observed by Sciacca et al. [30] is therefore
most likely due to the above mentioned methodological differ-
ences.
A methodologically challenging aspect that has not been
investigated in great detail is the question of hybrid receptors
formed between the IR and IGF-1R and their importance for
mediating mitogenic responses. Evidence suggests that hybrid
receptors bind insulin with the same affinity as IGF-1R [17] and it
could be speculated that the increased mitogenic potency of
analogues with increased affinity for the IGF-1R in fact was
mediated via IR/IGF-1R hybrid receptors. Some cancer cells
express higher levels of IR-A and IGF-1R and hence form Hybrid-
5
4
3
2
1
0
p
I
R
9
7
2
5
4
3
2
1
0
p
I
R
1
1
5
8
5
4
3
2
1
0
p
I
R
1
3
3
4
p
I
R
9
7
2
p
I
R
1
1
5
8
p
I
R
1
3
3
4
Ligand [nM] Ligand [nM] Ligand [nM]
Juxtamembrane C terminal Kinase
IR-A
IR-B
10–1 10–3 10–5 01 0 0 101 103 105 107
5
4
3
2
1
0
Ligand [nM]
10–1 10–3 10–5 01 0 0 101 103 105 107
5
4
3
2
1
0
Ligand [nM]
10–1 10–3 10–5 01 0 0 101 103 105 107
5
4
3
2
1
0
Ligand [nM]
10–1 10–3 10–5 01 0 0 101 103 105 107
10–1 10–3 10–5 01 0 0 101 103 105 107 10–1 10–3 10–5 01 0 0 101 103 105 107
Juxtamembrane C terminal Kinase
Human insulin Insulin detemir Insulin glargine Insulin X10 IGF-1
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Table 3. Relative potencies for activation of insulin receptor isoforms A and B at different phosphorylation sites.
IR-A IR-B
Juxta-membrane Kinase C-terminal Juxta-membrane Kinase C-terminal
Human insulin 100 100 100 100 100 100
Insulin X10 409 284 197 638 420 246
Insulin detemir 3.1 4.7 4.2 3.7 4.6 3.6
Insulin glargine 34.0 36.5 40.8 35.2 38.4 39.9
IGF-1 8.0 7.6 5.7 1.1 1.1 0.7
Data are means 6 SE, n=4.
IGF-1, insulin-like growth factor 1.
doi:10.1371/journal.pone.0034274.t003
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e34274A receptors [31]. In the light of evidence that Hybrid-A has
a higher affinity for human insulin than Hybrid-B [33], it could be
speculated that insulins with high affinities for Hybrid-A could
drive cancer growth through activation of Hybrid-A. However, in
previous studies we did not find Hybrid-A to bind insulin with high
affinity; in contrast we found that the two splice variants of hybrid
receptors bind insulin with similar low affinity [17]. In this study
we included X10, glargine and detemir in order to test their
affinities for hybrid receptors and explore whether these differ
between the two splice variants of hybrid receptors. We did not
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Figure 5. Dose-response curves for activation of the IGF-1
receptor. Data were obtained using BHK cells overexpressing human
IGF-1R with immunometric assay for phosphorylated IGF-1R, and are
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1; IGF-1R, insulin-like growth factor 1 receptor.
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Table 4. The specific antibody binding capacity (SABC) for
human mammary epithelial cells (HMEC) and L6-hIR cells.
Cell type Insulin Receptor IGF-1R IR:IGF-1R ratio
L6-hIR 204112622856 N/A 2:1*
HMEC 10236168 2131364279 1:21
The SABC (average number of antibodies capable of binding to each cell) was
measured using either the murine monoclonal antibody 83–7 recognising the
human IR or 24–31 recognising the human IGF-1R. Data represent mean (6SD)
of at least three independent experiments. No antibody is available that
recognises the extracellular domains of the rat IGF-1R, therefore it is not
possible to determine the relative number of rat IGF-1R on L6-hIR
cells.*unpublished results obtains by Western blot.
IGF-1R, insulin-like growth factor 1 receptor; N/A, not applicable.
doi:10.1371/journal.pone.0034274.t004
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e34274find significant differences in binding between the two hybrid
receptor splice variants for any of the analogues tested in this
study. However, we did find that X10 and glargine, which had
relatively higher affinity for IGF-1R, also bound to both hybrid
receptors with three-fold higher affinities than human insulin. In
contrast, detemir bound both hybrid receptors with a four-fold
decreased affinity compared to human insulin. Compared to the
high affinity IGF-1 binding to hybrid receptors, the tested
analogues bound at a level of 0.3–5% affinity. The selectivity
between IGF-1 and the tested analogues for hybrid receptors were
at the same level as for their cognate homodimer receptors.
The cell lines employed in mitogenicity testing contained
different levels of IRs and IGF-1Rs (Table 4). It is assumed that
hybrid receptors formed between IRs and IGF-1Rs occurs in
a random fashion in the ER. If this is the case then the level of IR
in hybrid receptors can be calculated by the mathematical formula
1/([IR]/[IGF-1R]+1) [34]. Then HMEC cells would have 95% of
their IR bound in hybrid receptors. The level of insulin-responsive
homodimer receptors would then be significantly decreased
compared to the expected level in hybrid receptor formation.
The two insulin analogues, X10 and glargine, were the only
insulin analogues we have tested that had a higher affinity to
hybrid receptors compared to human insulin. It can be speculated
that some of the mitogenicity of these two analogues may be
through activation of hybrid receptors, as their affinity was
comparable to homodimer IGF-1R affinity.
We have previously reported that sustained signalling from the
IR correlated with an increased mitogenic potency of an insulin
analogue [14]. In this study, we have now extended our previous
finding by examining three different IR phosphorylation sites, the
two isoforms and also the extent of signalling from the IGF-1R.
The overall conclusion from these studies is that only X10 displays
sustained signalling from the IR and only IGF-1 displays sustained
signalling from the IGF-1R. For each ligand, no major differences
were seen between the different phosphorylation sites. The only
exception was that C-terminal phosphorylation seems to decline
a little faster after stimulation with IGF-1. By comparing the
duration of signalling from IR-A with that of IR-B it seems that the
signal declines slightly faster from IR-B, which was a general
feature observed for all ligands and all phosphorylation sites. The
significance of this phenomenon remains to be elucidated.
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Table 5. Relative mitogenic potencies in L6-hIR cells and
human mammary epithelial cells (HMEC).
Mitogenic potency relative to human insulin (%)
L6-hIR HMEC
Human insulin 100 100
Insulin X10 617661 10986235
Insulin glargine 4969 6506136
Insulin detemir 9621 7 63
IGF-1 361 496461225
Potencies are presented as mean (6SE) from $9 independent experiments.
doi:10.1371/journal.pone.0034274.t005
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e34274The data presented herein clearly show that insulin analogues
with an increased affinity for the IGF-1R also have an increased
mitogenic potency in cells expressing many IGF-1 receptors. Thus,
X10 and glargine both display increased mitogenic potencies in
HMEC cells, which express approximately 21-fold more IGF-1
than insulin receptors. X10, but not glargine, also displays an
increased mitogenic potency in cells predominantly expressing IR.
Therefore, it seems clear that glargine mediates its increased
mitogenic potency through the IGF-1R and not through the IR.
This conclusion is also supported by studies by Shukla et al. [26]
where IGF-1R receptor levels were knocked down by siRNA
technique and earlier studies by Eckardt et al. [35], in which IGF-
1R levels were manipulated by clone selection procedures.
X10 displays an increased relative mitogenic potency in both
cell types employed in this study, which predominantly express
either the IR (L6-hIR cells) or the IGF-1R (HMEC); thus X10
seems to be able to evoke an increased mitogenic response through
both mechanisms shown in Fig. 1. As previously shown [14], X10
displays a greatly sustained signalling from the IR and we have
now extended that observation to include both receptor isoforms
and several IR phosphorylation sites, while we also have excluded
the possibility that X10 is able to induce sustained signalling from
the IGF-1R. Finally, we have found indications for a preferential
phosphorylation of the most N-terminal phosphorylation sites after
stimulation with X10. Further research is needed in order to
dissect which of these mechanisms is the most important factor
driving the increased mitogenic potency of X10 in cells via the IR.
The finding that substantial differences exist between cell types
underscores the need for proper characterisation of the cell
systems applied for mitogenicity studies. The receptor number and
effects of native ligands and the positive control X10 is especially
important.
At present, it is unknown which of the two main mechanisms, or
a combination thereof (depicted in Fig. 1), accounted for the dose-
dependent increase in the incidence of mammary tumours in
female Sprague-Dawley rats observed after stimulation with X10
[8]. There is a strong need for improved animal models in order to
test the tumour-promoting effects of insulin analogues. Ideally,
such a model should be a diabetic and/or an insulin resistant
model, since this would avoid the very low glucose levels seen in
traditional animal toxicological studies and therefore resemble the
clinical situation more closely. Once available, such models would
allow a more detailed correlation between in vitro molecular
characteristics and in vivo tumour promoting effects of insulin and
insulin analogues.
In summary, our data show that neither glargine nor detemir
differ from human insulin in their relative affinities for the two IR
isoforms (either in homodimer form or as hybrid receptors with
IGF-1R), or in their ability to stimulate the three studied IR
phosphorylation sites or in signalling kinetics; neither analogue has
an increased mitogenic effect in cells that express predominantly
IR. X10 and glargine do, however, display an increased relative
binding affinity for the IGF-1 receptor compared to the insulin
receptor (versus human insulin) and consequently exhibit in-
creased mitogenic activities in cells predominantly expressing IGF-
1R. X10 displays an increase in the relative IGF-1R:IR affinity
ratio as well as prolonged IR signalling kinetics and is more
mitogenic than human insulin in both IR and IGF-1R-expressing
cells. Importantly, none of the molecular data presented in this
paper give rise to any safety concern with detemir.
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